Grantham, Mayo, Van Otterloo & Co (GMO)
JNCE

Grantham, Mayo, Van Otterloo & Co (GMO)’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,400
Closed -$49K – 846
2020
Q1 		$49K Buy
+10,400
New +$59.9K ﹤0.01% 738

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s JNCE Position: Q2 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2020, closing a stake of 10,400 shares — an estimated $49K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in JNCE in Q1 2020 and held it in 1 quarter. The position peaked at $49K in Q1 2020. 90 funds tracked by Wall St. Rank hold JNCE as of Q2 2020.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 10,400 Jounce Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $49K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Jounce Therapeutics, Inc. Common Stock position peaked at $49K in Q1 2020.
  • 90 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2020, filed 13 Aug 2020.